Abstract 83P
Background
The role of Helicobacter bilis (H.bilis) in the development of inflammatory bowel disease (IBD) and colitis-associated carcinogenesis (CAC) has seldom been investigated.
Methods
Using 16S rRNA fluorescence in situ hybridization (FISH), we examined the abundance of H.bilis in 58 colorectal cancers (CRCs), 20 IBDs, 40 normal colorectal mucosae (NCs) and 20 adenomas (ADs). Number of CD4+CD45RB+T cell and expression of IFN-γ and TNF-α in these tissues was determined by immunofluorescence.
Results
The abundance of H.bilis was significantly higher in CRCs (33.7±27.7) than that in IBDs (15.0±16.3; P = 0.006), ADs (4.01±7.3; P < 0.001) and NCs (1.1±3.0; P < 0.0001). The abundance of H.bilis in IBDs was significantly higher than that in ADs (P = 0.013). Moreover, the average number of CD4+CD45RB+T cell was significantly higher in CRCs (5.7±3.2) than that in IBDs (1.9±1.8, P = 0.013) and NCs (1.0±1.0, P = 0.008). In addition, there was a positive correlation between the H.bilis abundance and density of CD4+CD45RB+T cells in 30 colorectal tissues (including 19 CRCs, 6 IBDs and 5 NCs) (Spearman correlation coefficients 0.6625, 95%CI 0.3875-0.8292, P < 0.0001). The frequency of co-staining for CD4+CD45RB+T cells and IFN-γ was significantly higher in H.bilis positive group (including 5 CRCs and 4 IBDs)than that in H.bilis negative group (including 5 CRCs and 4 IBDs) (P = 0.002).
Conclusions
H.bilis may play a role in the initiation of IBD and CAC, possibly through promoting the transformation of T cells into CD4+CD45RB+T cells and increasing the expression of proinflammatory cytokines IFN-γ.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiangsheng Fu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract